Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx® and Arcoxia®
摘要:
The preparation of the sulfoxide analogues 2 and 4, and their enantiomeric pure forms is discussed as well as their potential to act as prodrugs to the potent and selective sulfone-containing COX-2 inhibitors rofecoxib and etoricoxib. Sulfoxides 2 and 4 were shown to be effectively transformed in vivo into rofecoxib and etoricoxib, respectively, after oral administration in rats. In the case of sulfoxide 2, both a slightly improved pharmacokinetic profile and a better pharmacological activity in an arthritis model were seen when compared with rofecoxib. (c) 2006 Elsevier Ltd. All rights reserved.
2,3'-bipyridines derivatives as selective cox-2 inhibitors
申请人:Caturla Javaloyes Francisco Juan
公开号:US20060229338A1
公开(公告)日:2006-10-12
The present invention relates to 2,3′-bipyridines of formula (I), processes for their preparation, pharmaceutical compositions containing them, and their medical uses.